391 related articles for article (PubMed ID: 29181840)
21. Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of Waldenström macroglobulinemia.
Gayet M; Leymarie V; Derouault P; Guérin E; Vaidié J; Pascal V; Boulin M; Dmytruk N; Chauzeix J; Trimoreau F; Gachard N; Feuillard J; Rizzo D
Cytometry B Clin Cytom; 2022 Jan; 102(1):62-69. PubMed ID: 33634586
[TBL] [Abstract][Full Text] [Related]
22. Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.
Sewastianik T; Guerrera ML; Adler K; Dennis PS; Wright K; Shanmugam V; Huang Y; Tanton H; Jiang M; Kofides A; Demos MG; Dalgarno A; Patel NA; Nag A; Pinkus GS; Yang G; Hunter ZR; Jarolim P; Munshi NC; Treon SP; Carrasco RD
Blood Adv; 2019 Nov; 3(21):3360-3374. PubMed ID: 31698464
[TBL] [Abstract][Full Text] [Related]
23. Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Talaulikar D; Joshua D; Ho PJ; Gibson J; Quach H; Gibbs S; Ling S; Ward C; Augustson BM; Trotman J; Harrison SJ; Tam CS;
Intern Med J; 2023 Apr; 53(4):599-609. PubMed ID: 36441109
[TBL] [Abstract][Full Text] [Related]
24. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
[No Abstract] [Full Text] [Related]
25. Positive selection and high sensitivity test for MYD88 mutations using locked nucleic acid.
Albitar A; Ma W; DeDios I; Estella J; Agersborg S; Albitar M
Int J Lab Hematol; 2016 Apr; 38(2):133-40. PubMed ID: 26797804
[TBL] [Abstract][Full Text] [Related]
26. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.
Gustine JN; Tsakmaklis N; Demos MG; Kofides A; Chen JG; Liu X; Munshi M; Guerrera ML; Chan GG; Patterson CJ; Meid K; Dubeau T; Yang G; Hunter ZR; Treon SP; Castillo JJ; Xu L
Br J Haematol; 2019 Jan; 184(2):242-245. PubMed ID: 30183082
[TBL] [Abstract][Full Text] [Related]
27. Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.
Hunter ZR; Yang G; Xu L; Liu X; Castillo JJ; Treon SP
J Clin Oncol; 2017 Mar; 35(9):994-1001. PubMed ID: 28294689
[TBL] [Abstract][Full Text] [Related]
28. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.
Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Tsakmaklis N; Kanan S; Castillo JJ; Treon SP
Br J Haematol; 2015 Mar; 168(5):701-7. PubMed ID: 25371371
[TBL] [Abstract][Full Text] [Related]
29. MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders.
Ondrejka SL; Lin JJ; Warden DW; Durkin L; Cook JR; Hsi ED
Am J Clin Pathol; 2013 Sep; 140(3):387-94. PubMed ID: 23955458
[TBL] [Abstract][Full Text] [Related]
30. A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.
Varettoni M; Zibellini S; Boveri E; Klersy C; Candido C; Rattotti S; Ferretti VV; Defrancesco I; Mangiacavalli S; Nizzoli ME; Flospergher E; Zerbi C; Bergamini F; Benvenuti P; Brociner M; Merati G; Paulli M; Arcaini L
Br J Haematol; 2019 Nov; 187(4):441-446. PubMed ID: 31276195
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.
Varettoni M; Arcaini L; Zibellini S; Boveri E; Rattotti S; Riboni R; Corso A; Orlandi E; Bonfichi M; Gotti M; Pascutto C; Mangiacavalli S; Croci G; Fiaccadori V; Morello L; Guerrera ML; Paulli M; Cazzola M
Blood; 2013 Mar; 121(13):2522-8. PubMed ID: 23355535
[TBL] [Abstract][Full Text] [Related]
32. Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Talaulikar D; Tam CS; Joshua D; Ho JP; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Horvath N; Lee C; Zannettino A; Brown R; Augustson B; Jaksic W; Gibson J; Kalff A; Johnston A; Trotman J; Kalro A; Grigoriadis G; Ward C; Prince HM
Intern Med J; 2017 Jan; 47(1):35-49. PubMed ID: 28076910
[TBL] [Abstract][Full Text] [Related]
33. Waldenström macroglobulinemia.
Treon SP; Hunter ZR; Castillo JJ; Merlini G
Hematol Oncol Clin North Am; 2014 Oct; 28(5):945-70. PubMed ID: 25212891
[TBL] [Abstract][Full Text] [Related]
34. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.
Treon SP; Xu L; Guerrera ML; Jimenez C; Hunter ZR; Liu X; Demos M; Gustine J; Chan G; Munshi M; Tsakmaklis N; Chen JG; Kofides A; Sklavenitis-Pistofidis R; Bustoros M; Keezer A; Meid K; Patterson CJ; Sacco A; Roccaro A; Branagan AR; Yang G; Ghobrial IM; Castillo JJ
J Clin Oncol; 2020 Apr; 38(11):1198-1208. PubMed ID: 32083995
[TBL] [Abstract][Full Text] [Related]
35. MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome.
Poulain S; Boyle EM; Roumier C; Demarquette H; Wemeau M; Geffroy S; Herbaux C; Bertrand E; Hivert B; Terriou L; Verrier A; Pollet JP; Maurage CA; Onraed B; Morschhauser F; Quesnel B; Duthilleul P; Preudhomme C; Leleu X
Br J Haematol; 2014 Nov; 167(4):506-13. PubMed ID: 25160558
[TBL] [Abstract][Full Text] [Related]
36. Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Burnworth B; Wang Z; Singleton TP; Bennington A; Fritschle W; Bennington R; Brodersen LE; Wells DA; Loken MR; Zehentner BK
Leuk Res; 2016 Dec; 51():41-48. PubMed ID: 27890075
[TBL] [Abstract][Full Text] [Related]
37. Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression.
Amaador K; Vos JMI; Pals ST; Kraan W; Dobber JA; Minnema MC; Koene HR; de Bruin PC; Zwinderman AH; Kersten MJ
Leuk Lymphoma; 2022 May; 63(5):1070-1079. PubMed ID: 34961399
[TBL] [Abstract][Full Text] [Related]
38. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
Yang G; Buhrlage SJ; Tan L; Liu X; Chen J; Xu L; Tsakmaklis N; Chen JG; Patterson CJ; Brown JR; Castillo JJ; Zhang W; Zhang X; Liu S; Cohen P; Hunter ZR; Gray N; Treon SP
Blood; 2016 Jun; 127(25):3237-52. PubMed ID: 27143257
[TBL] [Abstract][Full Text] [Related]
39. Detection of the MYD88
Wu YY; Jia MN; Cai H; Qiu Y; Zhou DB; Li J; Cao XX
Ann Hematol; 2020 Aug; 99(8):1763-1769. PubMed ID: 32577844
[TBL] [Abstract][Full Text] [Related]
40. Highly sensitive
Drandi D; Genuardi E; Dogliotti I; Ferrante M; Jiménez C; Guerrini F; Schirico ML; Mantoan B; Muccio V; Lia G; Zaccaria GM; Omedè P; Passera R; Orsucci L; Benevolo G; Cavallo F; Galimberti S; Sanz RG; Boccadoro M; Ladetto M; Ferrero S
Haematologica; 2018 Jun; 103(6):1029-1037. PubMed ID: 29567768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]